For laboratory research use only - not for human consumption

Compound hub · PT-141

How does PT-141 work?

PT-141 (bremelanotide) switches on several melanocortin receptors. The FDA label ranks them by potency as MC1R, MC4R, MC3R, MC5R and MC2R. It says MC1R and MC4R matter most at therapeutic exposure, which means the levels reached in treatment. The same label says how the approved product works in low sexual desire is unknown. The full path from receptor to desire has not been shown.

Published 2026-10-16Updated 2026-10-16Written by Form Laboratories research team5 min read

A receptor is a docking site on the surface of a cell. When the right molecule fits, the cell changes what it does. Your skin cells, your brain and your adrenal glands all carry docking sites for one family of messengers. They are called melanocortins. PT-141 switches on several of these docking sites. It is the subject of the PT-141 hub.

This page splits three things that web pages often blur. First, which receptors bremelanotide binds. Second, what researchers think that binding might do. Third, what the body does with the peptide afterwards. For the basics, start with what PT-141 is.

Key facts

Key facts for How does PT-141 work? Melanocortin receptors and what the label says
Drug classMelanocortin receptor agonist (FDA label, 2019)
Receptors activatedMC1R, MC4R, MC3R, MC5R and MC2R, in that order of potency (FDA label, 2019)
Receptors most relevant at therapeutic exposureMC1R and MC4R (FDA label, 2019)
Mechanism for low sexual desireUnknown (FDA label, 2019)
Time to peak level in plasma, medianAbout 1.0 hour, range 0.5 to 1.0 (FDA label, 2019)
Terminal half-life, meanAbout 2.7 hours, range 1.9 to 4.0 (FDA label, 2019)
Main breakdown routeHydrolysis (splitting by water) of the amide bonds of the ring (FDA label, 2019)
Label sourceDrugs@FDA label for NDA 210557, 2019
FDA label, 2019Journal of Biological Chemistry 2015

What are melanocortin receptors?

Melanocortin receptors are a family of five docking sites on cells, named MC1R to MC5R. They respond to melanocortin messengers such as alpha-melanocyte-stimulating hormone. The FDA label for bremelanotide names all five. It says MC1R sits on melanocytes, the cells that make skin pigment. When a molecule binds MC1R there, the cell makes more melanin and pigmentation increases. The label also says nerve cells with MC4R are found in many parts of the central nervous system. That is the brain and spinal cord. These receptors sit in different tissues. So one molecule that binds several of them can reach several body systems.

The label does not describe the jobs of MC2R, MC3R or MC5R, and this page does not guess. The point here is small. A skin receptor and a brain receptor can respond to the same peptide. That fact alone does not explain every side effect in the label. The side-effects page sets out those records.

Diagram of one key-shaped messenger with arrows to a docking site on a skin pigment cell and on a nerve cell. Labels read Skin cell, Nerve cell, MC1R and MC4R.
MC1R sits on melanocytes, the skin's pigment cells, and nerve cells carrying MC4R are found in many parts of the brain and spinal cord. Binding at these two receptors matters most at therapeutic exposure. Source: FDA label for Vyleesi, 2019.
FDA label, 2019Obstetrics & Gynecology 2019

Which receptors does bremelanotide activate?

Bremelanotide is a nonselective agonist. An agonist is a molecule that switches a receptor on. Nonselective means it switches on several receptor types, not just one. The FDA label ranks the five receptors by potency: MC1R, MC4R, MC3R, MC5R, then MC2R. It says that at therapeutic exposure, binding at MC1R and MC4R matters most. Kingsberg and colleagues describe it as a ring-shaped, seven-amino-acid version of alpha-melanocyte-stimulating hormone. They say it binds tightly to the melanocortin-4 receptor. The sources opened for this page give no binding constants for bremelanotide. So this page gives no number for how tightly it binds.

Order of potency means which receptor responds most easily to the same molecule. Picture five locks and one key. The key turns some locks more easily than others. The ranking says which locks turn first. It is not a map of what each receptor does in a person.

FDA label, 2019Obstetrics & Gynecology 2019ClinicalTrials.gov NCT02333071ClinicalTrials.gov NCT02338960

Evidence limits

How does PT-141 affect sexual desire?

The FDA label says the way PT-141 affects sexual desire is unknown. In its words, the clinical mechanism of bremelanotide in hypoactive sexual desire disorder (HSDD) is unknown. That statement describes the 2019 label. It does not rule out later research. Kingsberg and colleagues write that preclinical work suggests an action on the brain's messenger pathways for desire and arousal. Preclinical means lab and animal studies. They do not claim a fully mapped human mechanism. The phase 3 trials measured desire and distress scores and counts of sexual events. None of those outcomes was brain chemistry.

The label does not show that bremelanotide raises dopamine, one of the brain's chemical messengers. The large trials did not measure dopamine either. A receptor can switch on without anyone showing the whole chain from receptor to behaviour.

A receptor result and a questionnaire answer are different kinds of evidence. A receptor test shows what happens at the docking site. A questionnaire shows what a woman reported. Neither one alone maps the path between the two. What the trials measured shows how narrow the measured outcome was.

FDA label, 2019

How does the body handle bremelanotide?

The FDA label records how the body handles the approved product after one under-the-skin administration. The level in plasma, the liquid part of blood, peaks after a median of about 1.0 hour. Absolute bioavailability is about 100%. That is the share that reaches the bloodstream. The average terminal half-life is about 2.7 hours, with a range of 1.9 to 4.0 hours. The body breaks the peptide down by hydrolysis. Water splits the amide bonds that hold its ring together. In a study with a radioactive tag on the peptide, 64.8% of the radioactivity was found in urine and 22.8% in faeces.

Half-life is the time the plasma level takes to fall by half once absorption is done. These figures belong to the approved product in the label's studies. The sources opened for this page give no half-life for any other material, so none is stated here.

The table below lists the label's main figures, each with a plain meaning beside it.

Comparison

Values recorded in the FDA label for bremelanotide after one under-the-skin administration. They describe the approved product in the label's studies, not other material.

Comparison: How does PT-141 work? Melanocortin receptors and what the label says
MeasureLabel valuePlain meaning
Median time to peak levelAbout 1.0 hour (range 0.5 to 1.0)How long the plasma level takes to reach its highest point
Absolute bioavailabilityAbout 100%The share of the peptide that reaches the bloodstream after an under-the-skin administration
Bound to serum protein21%The share carried attached to proteins in blood
Volume of distribution25.0 ± 5.8 LA calculated figure that links the amount in the body to the plasma level
Mean terminal half-lifeAbout 2.7 hours (range 1.9 to 4.0)Time for the plasma level to halve once absorption is done
Mean clearance6.5 ± 1.0 L per hourHow fast the body removes the peptide from plasma

FAQ

Does PT-141 act on the brain?

The FDA label says nerve cells with the MC4R receptor are found in many parts of the central nervous system. It also says binding at MC4R is among the most relevant at therapeutic exposure. The same label says the mechanism for low sexual desire is unknown.

Is PT-141 a vasodilator or an erectile drug?

The FDA label calls bremelanotide a melanocortin receptor agonist. It does not give an erectile-function use. The approved product is not indicated in men. The sources opened for this page include no erectile-function trial.

Why does PT-141 darken skin in some people?

The label explains the likely route. MC1R sits on melanocytes, the skin's pigment cells. Binding there leads to more melanin and more pigmentation. Focal hyperpigmentation means patches of darker skin. It appears among the label's warnings. The side-effects page gives the figures.

Is the half-life the same for every PT-141 product?

Not established. The 2.7-hour figure comes from the label's studies of the approved product. The sources opened for this page give no half-life for other PT-141 material.

Citations

2 sources
  1. Kingsberg SA, Clayton AH, Portman D, et al. Obstetrics & Gynecology. 2019;134(5):899-908.
    doi:10.1097/AOG.0000000000003500

  2. Yang Y, Mishra V, Crasto CJ, et al. Journal of Biological Chemistry. 2015;290(12):7685-7692.
    doi:10.1074/jbc.M114.596122

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease